OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

Inclusion Criteria: * Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV * No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis * Envisaged surgical candidate for interval debulking after 2 cycles of treatment * Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures * ECOG 0-2 * Written informed consent according to national legal and regulatory requirements prior to any project specific procedures Exclusion Criteria: * Elevated liver enzymes (double of normal range: ASAT \> 68 U/l; ALAT \> 82 U/l; GGT \> 80 U/l) * Elevated creatinine (double of normal range: \>120 mmol/l)) * ECOG ≥3 * Pregnant or lactating women * Any other malignancy within the last 5 years which has an impact on the prognosis of the patient * Inability to swallow tablets * Concurrent participation in another clinical trial on the same indication * Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the sponsor-project leader may interfere with the project or affect patient compliance